An open-label, DDI study to investigate the effects of amlitelimab on the PK of selected cytochrome P450 substrates

Trial Identifier:	INT18404
Sponsor:	Sanofi
Start Date:	November 2024
Primary Completion Date:	November 2025
Study Completion Date:	April 2026
Condition:	Eczema

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
GERMANY	BERLIN, GERMANY, 10117

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.